The Role of PSMB5 in Sodium Arsenite-induced Oxidative Stress in L-02 Cells
Overview
Authors
Affiliations
Endemic arsenism is widely distributed in the world, which can damage multiple organs, especially in skin and liver. The etiology is clear, but the mechanisms involved remain unknown. Ubiquitin-proteasome pathway (UPP) is the main pathway regulating protein degradation of which proteasome subunit beta type-5(PSMB5) plays a dominant role. This paper aims to study the role and mechanism of PSMB5 in sodium arsenite (NaAsO)-induced oxidative stress liver injury in L-02 cells. Firstly, L-02 cells were exposed to different concentrations of NaAsO to establish a liver injury model of oxidative stress, and then mechanisms of oxidative stress were studied with carbobenzoxyl-leucyl-leucl-leucll-line (MG132) and knockdown PSMB5 (PSMB5-siRNA). The oxidative stress indicators, levels of 20S proteasome, the transcription and protein expression levels of PSMB5, Cu-Zn superoxide dismutase (SOD1), and glutathione peroxidase 1 (GPx1) were detected. The results demonstrated that NaAsO could induce oxidative stress-induced liver injury and the activity of 20S proteasome and the protein expression of PSMB5, SOD1, and GPx1 decreased. After MG132 or PSMB5-siRNA pretreatment, the gene expression of PSMB decreased. After MG132 or PSMB5-siRNA pretreatment, and then L-02 cells were treated with NaAsO, the gene expression of PSMB remarkably decreased; however, the protein expression of SOD1 and GPx1 increased. Overall, NaAsO exposure could induce oxidative stress liver injury and low expression of PSMB5 in L-02 cells, and PSMB5 might play an important role in the regulation of oxidative stress by regulating the expression of SOD1 and Gpx1.
Zhang X, Li Y Anticancer Agents Med Chem. 2024; 24(17):1264-1274.
PMID: 39034728 DOI: 10.2174/0118715206312004240712072532.
Liu J, Mi J, Liu S, Chen H, Jiang L FEBS Open Bio. 2022; 12(11):2025-2041.
PMID: 36062301 PMC: 9623531. DOI: 10.1002/2211-5463.13479.
Han L, Hao Y, Wu X, Hu D Dis Markers. 2022; 2022:2329904.
PMID: 36061354 PMC: 9439905. DOI: 10.1155/2022/2329904.
Hu T, Shen L, Huang Q, Wu C, Zhang H, Zeng Q Front Pharmacol. 2021; 12:749035.
PMID: 34899304 PMC: 8660860. DOI: 10.3389/fphar.2021.749035.